Dr Belinda Quinn is a trained medical doctor, a specialised clinical researcher in neurology and a commercially focused Director. She joined the Precision Medicine Catapult (PMC) in 2015 as Chief Clinical Officer and became Chief Executive Officer in April 2016.
Before joining the PMC, Belinda was interim Director for MHRA where she led teams of researchers, scientists and IT specialists using technology to establish Pragmatic Real World studies for pharma.
As Executive Director for a UK hospital, Belinda was responsible for delivering clinical and IT risk reviews. She delivered ‘best of breed’ solutions, allowing the hospital to operate with unmatched security, reliability and flexibility. Belinda has held senior roles in public healthcare both in the UK and Australia and has been a Vice President of GlaxoSmithKline and Associate Partner at Accenture.
James Peach has worked in the medical industry since 2005, and joined the PMC in January 2017 as Chief Operating Officer, following three years as Managing Director of the Main Programme of Genomics England.
He brings a huge amount of experience to the PMC. During his time at Genomics England, James oversaw the establishment of the world’s largest whole genome sequencing operation embedded in routine care across the NHS, for patients with rare inherited diseases and cancer. Prior to his role at Genomics England, James was a partner at Syncona – the Wellcome Trust healthcare investment partnership – and set up and led the Cancer Research UK Stratified Medicine Programme, a cancer genetics partnership with AstraZeneca and Pfizer.
James has also been a member of the Department of Health’s Emerging Science and Bioethics Advisory Committee, and the Human Genomics Strategy Group. His early career was in management consulting at McKinsey & Company and Credo.
Professor Joanne Hackett has been actively involved in clinical research for over 15 years in Canada, America, Germany, Sweden and the UK. She joined the PMC in October 2016.
An accomplished entrepreneur, scientist and strategist, Joanne has experience in the execution and management of complex business transactions, as well as broad business development experience in negotiation, execution and management of hundreds of transactions with pharma, biotech, academia and non-profits organisations.
Dr Ruth Jamieson is seconded to the PMC from University College London (UCL) where she has spent the last five years involved in the strategic development of initiatives and funding bids and for experimental and personalised medicine. At the Catapult, Ruth’s role is to identify and assess precision medicine opportunities across the London academic, research and health landscape, and then identify those that best meet the criteria for the PMC to support and advance in line with the PMC’s emerging 5-year strategy and plan.
Ruth holds a PhD in Medical Genetics from St George’s Hospital Medical School, University of London. Following her academic career, Ruth moved into science funding, spending 11 years at the Wellcome Trust as a Science Portfolio Adviser working on a wide range of bioscience before joining UCL.